GlycoVaxyn AG Announces Addition of Gerd Zettlmeissl, as Chairman of the Board of Directors
3/6/2013 6:50:02 AM
More...
|
GlycoVaxyn AG Signs Exclusive License Agreement and Enters Research and Development Collaboration With Janssen Pharmaceuticals, Inc., to Develop Multi-Valent Bacterial Vaccine
1/4/2013 9:58:53 AM
More...
|
GlycoVaxyn AG Announces Strategic Collaboration With GlaxoSmithKline (GSK) to Develop New Bacterial Vaccines using GlycoVaxyn's Bio-Conjugation Technology
12/19/2012 9:05:22 AM
More...
|
GlycoVaxyn AG's Staphylococcus aureus Bioconjugate Vaccine Candidate Protects Mice Against Invasive S. aureus Infection
9/16/2011 10:37:06 AM
More...
|
GlycoVaxyn AG to Host Second Annual Science Day to Discuss Challenges and Opportunities in Vaccine Development
6/15/2011 7:03:59 AM
More...
|
GlycoVaxyn AG Phase I Clinical Study Shows Positive Data with Shigella Dysenteriae Vaccine Candidate
10/8/2010 9:39:22 AM
More...
|
GlycoVaxyn AG and a Harvard University Affiliated Hospital Receive USD 3.4 Million National Institutes of Health (NIH) Grant for Staphylococcus aureus Vaccine Development
5/4/2010 6:59:45 AM
More...
|
GlycoVaxyn AG's First Clinical Study with Bioconjugate Vaccine Initiated
2/23/2010 9:55:40 AM
More...
|
GlycoVaxyn AG Appoints Renowned Vaccinologist Dr Stanley Plotkin to Supervisory Board
10/6/2009 8:48:07 AM
More...
|
GlycoVaxyn AG Raises CHF 25 Million in Financing Led by Edmond de Rothschild Investment Partners
3/5/2009 7:42:38 AM
More...
|
|